Navigation Links
The Leukemia & Lymphoma Society Available to Comment on FDA Approval of Seattle Genetics' Adcetris, First New Treatment for Hodgkin Lymphoma Since 1977
Date:8/19/2011

WHITE PLAINS, N.Y., Aug. 19, 2011 /PRNewswire/ -- Today the Food and Drug Administration (FDA) approved Seattle Genetics' Adcetris to treat two types of rare blood cancers – Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL).

(Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO)

The drug is approved for Hodgkin lymphoma patients after failure of a stem cell transplant or two chemotherapy treatments and for ALCL patients after failure of at least one multi-agent chemotherapy treatment.

"This is a great advance for patients battling both of these diseases," said Hildy Dillon, Senior Vice President of Patient Services for The Leukemia & Lymphoma Society. "These are both considered very curable diseases but there is a population of patients from both diseases for whom treatment has not been effective."

Hodgkin lymphoma has an 86 percent survival and ALCL has an 80 percent cure rate.

"But for those people who don't respond well these can be very difficult cancers to cure. This advance gives new hope to that group of patients," Dillon said.

Dillon added that Seattle Genetics should be commended for investing in a therapy for a very small subgroup of patients who don't respond to standard therapy and for whom there were very limited options until now.

There are nearly 9,000 new cases of Hodgkin lymphoma diagnosed each year and 3,000 new cases of ALCL, and both diseases primarily impact children in their late teens and young adults.  Adcetris is a targeted therapy linking a tumor-targeting antibody to a chemotherapy drug with the goal of limiting side effects.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Perdue Kidd & Vickery Files Lawsuit Against Abbott Laboratories for Inadequate Leukemia and Cancer Warning
2. Recent Study Shows Leukothera™ Combined with Other Agents Has Enhanced Anti-Leukemia Effects
3. Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia
4. Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders
5. Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
6. Medco Partners With MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia
7. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides
8. Reportlinker Adds Triple Analysis: Breast Cancer, Leukemia and Cancer Vaccines
9. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer
10. Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis
11. Reportlinker Adds Triple Analysis: Colorectal Cancer, Leukemia and Apoptosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ) today ... quarter of 2013 on Monday, February 3, 2014. A press ... close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... the operating highlights and financial results for the fourth quarter ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), ... that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... The terms of the acquisition were not disclosed. ... company providing a wide range of sleep, mobility, and respiratory ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... issued today a shareholders, letter discussing the results of its fiscal ... Dear Imagenetix shareholder - Following ... we commence the new fiscal year, I would like to address ...   Over the past few years our primary strategy ...
... July 12, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... 1 clinical trial of APD811, an orally bioavailable agonist ... treatment of pulmonary arterial hypertension, or PAH. ... tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 ...
Cached Medicine Technology:Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 2Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 4
(Date:4/24/2014)... WINSTON-SALEM, N.C. April 24, 2014 ,Take me ... of apple slices and kale chips. The more likely ... of Crackerjacks. , Unfortunately for children who play ... may be contributing to weight problems, according to researchers ... in the current online edition of Childhood Obesity ...
(Date:4/24/2014)... Center for BrainHealth will bring together national experts ... challenges at its inaugural Brain Health Summit, titled ... speakers will include Dr. Sandra Bond Chapman, founder ... U.S. Senator Chuck Grassley (R-IA), U.S. Representative Chaka ... for Policy and Early Learning, U.S. Department of ...
(Date:4/24/2014)... to be boring and irrelevant, could offer an alternative ... Researcher Dr Milena Furtado, and her team from the ... the heart cell fibroblast is a close relative to ... heart. , In research published today in Circulation ... are unique cells due to their genetic program, and ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Boring cells could hold the key to heart disease 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Study: Altruistic adolescents less likely to become depressed 2
... day, March 20, we celebrate head injury awareness day. This ... annual incidences of head injuries. Every day, 500,000 people are ... or the other and it is the sixth most common cause ... globe in the U.S, every 15 seconds, a person suffers a ...
... this time. Beer, wine and spirits bottles will now be ... trying to conceive. The decision follows fears over ... officials warn of subsequent risks such as fetal alcohol syndrome ... have been protests from the liquor lobby that say that ...
... ‘disgusting’ reports that reveal millions of pounds being collected in ... , The figures disclosed under the Freedom of ... pounds being made during 2005/2006,some trusts raised more than one ... charges" on the weak and vulnerable. The top ...
... has undergone liver transplant is convalescing well. This was ... Russell Britz the Head of the Transplant Unit at ... minister needed this liver transplant very urgently and that ... operation done. ,The Measure for End Stage ...
... provide quality care to patients. In a recent report, ... scan results never reach the doctors table. The report ... ,Worse still, the results reach Doctors via informal ... a tacit agreement between the department and the Doctor ...
... persistent asthma have a level of control that is ... the journal of Ambulatory Pediatrics. ,"That leaves almost ... to," said the study's lead author, Jill Halterman, M.D., ... at Strong. "They may be experiencing unnecessary symptoms, missed ...
Cached Medicine News:Health News:Head Injury Awareness Day 2Health News:Head Injury Awareness Day 3Health News:Babies and Drinks Don’t Mi 2Health News:Easy Money-NHS Trusts Make Millions from Parking Fees 2Health News:Asthmatic Children Still Not Breathing Easier, Study Says 2
Large deep curve....
3 mm electrode Inserts - monopolar foot control connection....
... is an Auto Refractor/Keratometer with ... refinement. Electronic elevation, automatic alignment, ... accuracy and all the other ... Marco Automatic Refractors/Keratometer famous, make ...
Sterile perfluorocarbon for intraocular Application....
Medicine Products: